BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Fish and Richardson
Johnson and Johnson

Generated: December 14, 2017

DrugPatentWatch Database Preview

AVALIDE Drug Profile

« Back to Dashboard

When do Avalide patents expire, and what generic alternatives are available?

Avalide is a drug marketed by Sanofi Aventis Us and is included in one NDA.

The generic ingredient in AVALIDE is hydrochlorothiazide; irbesartan. There are thirty-one drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the hydrochlorothiazide; irbesartan profile page.
Drug patent expirations by year for AVALIDE

Pharmacology for AVALIDE

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Sanofi Aventis UsAVALIDEhydrochlorothiazide; irbesartanTABLET;ORAL020758-001Sep 30, 1997DISCNYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Sanofi Aventis UsAVALIDEhydrochlorothiazide; irbesartanTABLET;ORAL020758-004Mar 15, 2005DISCNYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Sanofi Aventis UsAVALIDEhydrochlorothiazide; irbesartanTABLET;ORAL020758-002Sep 30, 1997ABRXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Sanofi Aventis UsAVALIDEhydrochlorothiazide; irbesartanTABLET;ORAL020758-003Aug 31, 1998ABRXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for AVALIDE

Drugname Dosage Strength RLD Submissiondate
irbesartan and hydrochlorothiazideTablets300 mg/25 mgAvalide6/6/2006
irbesartan and hydrochlorothiazideTablets150 mg/12.5 mg and 300 mg/12.5 mgAvalide11/10/2004

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Cantor Fitzgerald
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch: